Related Experiment Video

Updated: Jul 3, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

[Pharmacogenetics and tumor sensitivity of antineoplastic agents. Application to colorectal cancer]

Gérard Milano1

  • 1Laboratoire d'oncopharmacologie, Centre régional de lutte contre le cancer de Nice Antoine-Lacassagne, 06189 Nice Cedex 02. gerard.milano@nice.fnclcc.fr

La Revue Du Praticien
|July 26, 2008
PubMed

Insights

Gene variations influence how anticancer drugs work for colorectal cancer. Specifically, UGT 1A1 gene polymorphisms may predict irinotecan treatment toxicity, guiding personalized medicine approaches.

Area of Science:

  • Pharmacogenomics
  • Oncology
  • Genetics

Context:

  • Colorectal cancer treatment involves various anticancer agents.
  • Gene polymorphisms in key enzymes like thymidylate synthase, methylenetetrahydrofolate reductase, and UGT 1A1 can affect drug efficacy and toxicity.
  • UGT 1A1 gene variations are particularly implicated in irinotecan treatment outcomes.

Purpose:

  • To explore the impact of gene polymorphisms on the pharmacodynamics of colorectal cancer treatments.
  • To identify UGT 1A1 polymorphisms as potential biomarkers for irinotecan-induced toxicity.
  • To highlight the ongoing clinical validation of germline genetic testing for personalized cancer therapy selection.

Summary:

  • Gene polymorphisms significantly influence the pharmacodynamics of anticancer drugs used in colorectal cancer therapy.
  • Specific polymorphisms in thymidylate synthase, methylenetetrahydrofolate reductase, and UGT 1A1 are relevant.
  • UGT 1A1 polymorphisms are recognized as potential indicators of irinotecan treatment toxicity risk.

Impact:

  • Germline genetic analyses are being clinically validated to personalize cancer treatment selection and dosage.
  • This research supports the development of precision medicine in oncology.
  • Identifying genetic predispositions to drug toxicity can improve patient safety and treatment effectiveness.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...